RNA editing is emerging as a powerful tool and therapeutic modality, with Wave Life Sciences announcing positive clinical data for AATD, and a new wave of companies entering the clinic; the aspiration of bringing efficacious editors to patients is ever closer to becoming a reality.
With the forging of important partnerships like Roche and Ascidian, and significant funding rounds like AIRNA’s $155m oversubscribed series B, the 6th RNA Editing Summit couldn’t come at a better time, returning to Boston this July to advance the discovery and development of RNA modifying therapies.
